CLINICAL_TRIALS withdrawal · 2018-05-14

Clinical Trial Update: Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects [Phase 2]

A Phase 2 trial evaluating MK-0677 (ibutamoren) for lean body mass in chronic kidney disease stage 4/5 has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: University of Virginia | Conditions: Chronic Kidney Disease, Kidney Disease | Phase 2 | Status: WITHDRAWN